1. –оссийские клинические рекомендации. –евматологи€/ под ред. ≈.Ћ. Ќасонова. Ц ћ.: √Ёќ“ј–-ћедиа, 2017. 464 с. [Revmatologiya: Klinicheskie rekomendatsii. Moscow: GEOTAR-Media; 2017. 464 p.] 2. јлекберова «.—. Ѕолезнь Ѕехчета: монографи€ / «. —. јлекберова. Ч ћ.: 2007. 86 с. 3. Hatemi G., Seyahi E., Fresko I., Talarico R., Hamuryudan V. One year in review 2017: Beh?etТs syndrome. Clinical and Experimental Rheumatology 2017; 35 (Suppl.108): S3-S15. 4. Singer O. Cogan and Behcet Syndromes. Rheum Dis Clin N Am 41, 2015, 75Ц91 http://dx.doi.org/10.1016/j.rdc.2014.09.007 5. Zeidan M.J., Saadoun D., Garrido M., Klatzmann D., Six A., Cacoub P. Beh?etТs disease physiopathology: a contemporary review. Autoimmun Highlights, 2016 Dec; 7 (1): 4. DOI 10.1007/s13317-016-0074-1 6. International Society for Beh?et Disease. ќфициальный сайт: http://www.behcetdiseasesociety.org (http://www.behcetdiseasesociety.org) 7. ѕостановление ѕравительства –‘ от 26.04.2012 є 403 Ђќ пор€дке ведени€ ‘едерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболевани€ми, привод€щими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегментаї. ќфициальный сайт правительства –‘: http://government.ru/docs/all/81971/ 8. International Study Group for Beh?etТs Disease. Criteria for diagnosis of Beh?etТs disease. Lancet 1990; 335: 1078-80. doi: http://dx.doi.org/10.1016/0140-736(90)92643-V 9. International Team for the Revision of the International Criteria for Beh?etТs Disease (ITR-ICBD). The International Criteria for Beh?etТs Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology, 2014, vol. 28, no. 3, pp. 338Ц347. 10. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Beh?et"s disease: international consensus recommendations. J Neurol. 2014 Sep; 261(9):1662-76. doi: 10.1007/s00415-013-7209-3. 11. ќвчаров ѕ. —., Ћисицына “. ј., ¬ельтищев ƒ. ё., “ардов ћ. ¬., Ѕуренчев ƒ. ¬., јлекберова «. —., Ќасонов ≈. Ћ. Ќеврологические и психические расстройства при болезни Ѕехчета. ∆урнал неврологии и психиатрии им. —.—.  орсакова. 2016;116(6): 76-86 (http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2016/6/1199772982016061076) 12. Bhakta B.B, Brennan P, James T.E, Chamberlain M.A, Noble B.A, Silman A.J. Beh?etТs disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38: 728Ц33. (http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2016/6/1199772982016061076)http://dx.doi.org/10.1093/rheumatology/38.8.728 (http://dx.doi.org/10.1093/rheumatology/38.8.728) 13. Lawton G., Bhakta B. B., Chamberlain M. A., Tennant A. The Beh?etТs Disease Activity Index. Rheumatology 2004;43:73Ц78. doi:10.1093/rheumatology/keg453 14. Zouboulis C., Vaiopoulos G., Macromichelakis N. et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades Ц BehcetТs disease in Greece. Clin. Exp. Rheum. 2003, 21, (suppl.30) S19 - S26 15. Taylor J, Glenny AM, Walsh T, Brocklehurst P, Riley P, Gorodkin R, Pemberton MN. Interventions for the management of oral ulcers in Beh?etТs disease. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD011018. DOI: 10.1002/14651858.CD011018.pub2. 16. Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M. Behcet"s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017 Jan;13(1):57-65. Epub 2016 Jul 11. Review. DOI: 10.1080/1744666X.2016.1205486 (https://www.ncbi.nlm.nih.gov/pubmed/27351485) 17. Alpsoy E. Beh?etТs disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. (https://www.ncbi.nlm.nih.gov/pubmed/27351485)J Dermatol. (https://www.ncbi.nlm.nih.gov/pubmed/27075942) 2016 Jun;43(6):620-32. doi: 10.1111/1346-8138.13381. 18. Yazici H (https://www.ncbi.nlm.nih.gov/pubmed/? term=Yazici%20H%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Seyahi E (https://www.ncbi.nlm.nih.gov/pubmed/? term=Seyahi%20E%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Hatemi G (https://www.ncbi.nlm.nih.gov/pubmed/? term=Hatemi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Yazici Y (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yazici%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=29296024) Beh?et syndrome: a contemporary view. Nat Rev Rheumatol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Hasan+Yazici+Beh%C3%A7et+syndrome%3A+a+contemporary+view+2018) 2018 Feb;14(2):107-119. doi: 10.1038/nrrheum.2017.208. 19. Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular Involvement of Beh?etТs Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. (https://www.ncbi.nlm.nih.gov/pubmed/24828904) 2015 Dec;49(3):298-306. doi: 10.1007/s12016-014-8425-z 20. Cunningham Et Jr, Tugal-Tutkun I, Khairallah M, Okada Aa, Bodaghi B, Zierhut M: Beh?et Uveitis. Ocul Immunol Inflamm 2017; 25: 2-6 21. Skef W, Hamilton MJ, Arayssi Th. Gastrointestinal Beh?et"s disease: A review World J Gastroenterol 2015 April 7; 21(13): 3801-3812. DOI: 10.3748/wjg.v21.i13.3801 22. Seyahi E: Beh?etТs disease: How to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol 2016; 30: 279-95 23. Kidd DP: Neurological complications of Beh?etТs syndrome. J Neurol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=KIDD+DP%3A+Neurological+complications+of+Beh%C3%A7et%E2%80%99s+syndrome.+J+Neurol+2017) 2017 Oct;264(10):21 2183. doi: 10.1007/s00415-017-8436-9 24. Leonardo N M, McNeil J. BehcetТs Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Leonardo+N+M%2C+McNeil+J.+Behcet%E2%80%99s+Disease%3A) 2015; V. 2015, Article ID 945262, 7 pages. http://dx.doi.org/10.1155/2015/945262 (http://dx.doi.org/10.1155/2015/945262) 25. Demirseren D.D., Ceylan G.G., Akoglu G., Emre S., Erten S., Arman A., Metin A. HLA-B51 subtypes in Turkish patients with Beh?etТs disease and their correlation with clinical manifestations. Genetics and Molecular Research, 2014,13 (3): 4788-4796 DOI http://dx.doi.org/10.4238/2014.July.2.8 26. јлекберова «.—., »змаилова ‘.»., √усева ».ј., ƒенисов Ћ.Ќ., √лухова —.»., ѕопкова “.¬. HLA-B5/51-генотип: св€зь с клиническими про€влени€ми болезни Ѕехчета (https://elibrary.ru/item.asp?id=24157443). Ќаучнопрактическа€ ревматологи€ (https://elibrary.ru/contents.asp?id=34108832). 2015. “. 53. є 4 (https://elibrary.ru/contents.asp?id=34108832&selid=24157443). —. 367-370. DOI; 10.14412/1995-4484-2015-367- 370 (https://doi.org/10.14412/1995-4484-2015-367-370) 27. Hatemi G, Christensen R, Bang D et al. 2018 update of EULAR recommendations for the management of Beh?etТs syndrome. Ann Rheum Dis 2018; 77: 808Ц818. doi: 10.1136/annrhumdis-2018-213225 28. –оссийские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (¬“Ёќ). ‘лебологи€ 2015, “.9, є 4, выпуск 2; с. 2-52. 29. Ќациональные рекомендации по ведению пациентов с аневризмами брюшной аорты. јнгиологи€ и сосудиста€ хирурги€ 2013; “. 19, є 2, приложение, с.2-74 30. –екомендации –оссийской гастроэнтерологической ассоциации и јссоциации колопроктологов –оссии по диагностике и лечению взрослых больных €звенным колитом. –оссийский журнал гастроэнтерологии, гепатологии, колопроктологии 2015; “. 25, є 1, с.48-65 31. Ozguler Y, Hatemi G. Management of Beh?etТs syndrome. Curr Opin Rheumatol. (http://www.ncbi.nlm.nih.gov/pubmed/26555450) 2016 Jan; 28(1): 45-50. doi: 10.1097/BOR.0000000000000231. 32. Aktulga E, Alta? M, M?ft?oglu A, et al. A double blind study of colchicine in Beh?etТs disease. Haematologica 1980; 65: 399Ц402. 33. Yurdakul S, Mat C, T?z?n Y, et al. A double-blind trial of colchicine in Beh?etТs syndrome. Arthritis Rheum 2001; 44: 2686Ц92. 34. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Beh?etТs disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19: 542Ц9 35. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Beh?etТs syndrome. N Engl J Med Overseas Ed 1990; 322: 281Ц5. 36. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Beh?et disease: a randomized placebocontrolled and double-blind study. Arch Dermatol 2002; 138: 467Ц71. 37. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Beh?etТs disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98Ц105. 38. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh?etТs syndrome Ч a phase 2, placebo-controlled study. N Engl J Med Overseas Ed 2015; 372: 1510Ц8. 39. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh?et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443Ц50. 40. Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Beh?etТs disease with anakinra: a pilot open-label study. Arthritis Res Ther 2017; 19: 69. 41. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant BehcetТs disease: a case series. Clin Rheumatol 2015; 34: 1293Ц301. 42. Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh?etТs disease: a multicenter retrospective study. Clin Rheumatol 2016; 35: 1281Ц6. 43. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120: 777Ц87. 44. Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Beh?etТs syndrome: report of two cases. Rheumatology 2013; 52: 1923Ц4. 45. Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Beh?etТs disease treated with tocilizumab. Clin Rheumatol 2015; 34: 1141Ц3. 46. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh?etТs disease: an open-label trial. Arthritis Rheum 2005; 52: 2478Ц84 47. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010; 94: 284Ц8. 48. Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Beh?etТs disease treated with interferon-alpha-2a. J Rheumatol 2008;35:896Ц903. 49. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh?etТs uveitis refractory to conventional treatments. Ophthalmology 2010;117: 1430Ц5. 50. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh?etТs disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31: 33Ц7. 51. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with BehcetТs disease receiving infliximab treatment. Br J Ophthalmol 2011;95:205Ц8. 52. Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Beh?etТs disease using infliximab. Clin Exp Rheumatol 2011;29(4 Suppl 67): S58Ц63. 53. Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with BehcetТs disease on infliximab therapy. Br J Ophthalmol 2011; 95:1245Ц50. 54. Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Beh?et disease. Arch Ophthalmol 2012; 130: 592Ц8 55. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh?etТs disease: a multicenter study. Ophthalmology 2014; 121: 1877Ц84. 56. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/ or refractory Beh?etТs disease: Multicenter study of 124 patients. J Autoimmun 2015;62:67Ц74. 57. Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Beh?etТs uveitis: a retrospective longterm follow-up study. Clin Exp Rheumatol 2014;32(4 Suppl 84): S 58Ц62 58. Jaffe GJ, Dick AD, Br?zin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med Overseas Ed 2016; 375: 932Ц43. 59. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebocontrolled phase 3 trial. Lancet 2016; 388: 1183Ц92 60. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121:785Ц796. 61. Atmaca LS, Yal?inda? FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Beh?etТs disease. Graefes Arch Clin Exp Ophthalmol 2007;245:451Ц6. 62. Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh?et disease. J Ocul Pharmacol Ther 2007; 23:395Ц401. 63. Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Beh?et disease. Ocul Immunol Inflamm 2014; 22: 27Ц33 64. Grekas D, Nikolaidis P, Karamouzis M, et al. Effects of azathioprine on ciclosporin metabolism. Nephron 1992; 60: 489. 65. Seyahi E., Yurdakul S. Beh?etТs Syndrome and Thrombosis. Mediterr J Hematol Infect Dis 2011, 3: e2011026 DOI 10.4084/MJHID.2011.026 66. Tayer-Shifman OE, Seyahi E, Nowatzky J, et al. Major vessel thrombosis in Beh?etТs disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol 2012;30:735Ц 40. 67. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with BehcetТs disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008;27:201Ц5. 68. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Beh?etТs disease. Arthritis Rheum 2012;64:2753Ц60. 69. Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Beh?et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine 2015;94:e494 70. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Beh?et syndrome. Am J Med 2004;117:867Ц70. 71. Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Beh?et?s syndrome: Effects of anti-TNF treatment. Semin Arthritis Rheum 2015;45:369Ц73 72. Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Beh?et disease: a series of 101 patients. Medicine 2012;91:18Ц24 73. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Beh?et disease: a series of 47 patients. Medicine 2012;91:35Ц48. 74. Park M-C, Hong B-K, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with BehcetТs disease. Clin Rheumatol 2007;26:1475Ц80 75. Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and longterm outcome of gastrointestinal involvement in BehcetТs syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine 2016;95:e3348. 76. Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38Цe45. 77. Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh?etТs syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol 2015;33(6 Suppl 94):S129Ц37. 78. Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-BehcetТs disease: case series and literature review. Clin Rheumatol 2011; 30: 1007Ц12. 79. Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Beh?et disease. Neurol Neuroimmunol Neuroinflamm 2016;3: e258 80. Shugaiv E, Tu?zu?n E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-BehcetТs disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011, 29 (4 Suppl 67): S64ЦS67 81. Kikuchi H, Aramaki K, Hirohata S Low dose MTX for progressive neuro-BehcetТs disease. A follow-up study for 4 years. Adv Exp Med Biol 2003, 528: 575Ц578 82. OТDuffy JD, Robertson DM, Goldstein NP Chlorambucil in the treatment of uveitis and meningoencephalitis of Behc,etТs disease. Am J Med 1984, 76: 75Ц84 83. Ait Ben Haddou EH, Imounan F, Regragui W et al. Neurological manifestations of Beh?etТs disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012, 168: 344Ц349 84. Noel N (http://www.ncbi.nlm.nih.gov/pubmed/? term=Noel%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Wechsler B (http://www.ncbi.nlm.nih.gov/pubmed/? term=Wechsler%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Nizard J (http://www.ncbi.nlm.nih.gov/pubmed/?term=Nizard%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Costedoat-Chalumeau N (http://www.ncbi.nlm.nih.gov/pubmed/?term=CostedoatChalumeau%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Boutin du LT (http://www.ncbi.nlm.nih.gov/pubmed/? term=Boutin%20du%20LT%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Dommergues M (http://www.ncbi.nlm.nih.gov/pubmed/? term=Dommergues%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Vauthier-Brouzes D (http://www.ncbi.nlm.nih.gov/pubmed/?term=VauthierBrouzes%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Cacoub P (http://www.ncbi.nlm.nih.gov/pubmed/?term=Cacoub%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Saadoun D (http://www.ncbi.nlm.nih.gov/pubmed/? term=Saadoun%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23780828). Beh?et"s disease and pregnancy. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/23780828#comments)Arthritis Rheum. (http://www.ncbi.nlm.nih.gov/pubmed/23780828) 2013 Sep; 65(9):2450-6. doi: 10.1002/art.38052. 85. Ben-Chetrit E (http://www.ncbi.nlm.nih.gov/pubmed/?term=BenChetrit%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25268664). Beh?et"s syndrome and pregnancy: course of the disease and pregnancy outcome. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/25268664#comments)Clin Exp Rheumatol. (http://www.ncbi.nlm.nih.gov/pubmed/25268664) 2014 Jul-Aug; 32 (4 Suppl 84):S93-8. 86. Hamza M., Ellench M., Zribi A. BehcetТs disease and pregnancy. Ann. Rheum. Dis. 1988, 47: 350 87. Jadaon J (http://www.ncbi.nlm.nih.gov/pubmed/? term=Jadaon%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Shushan A (http://www.ncbi.nlm.nih.gov/pubmed/? term=Shushan%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Ezra Y (http://www.ncbi.nlm.nih.gov/pubmed/?term=Ezra%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Sela HY (http://www.ncbi.nlm.nih.gov/pubmed/? term=Sela%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Ozcan C (http://www.ncbi.nlm.nih.gov/pubmed/?term=Ozcan%20C%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Rojansky N (http://www.ncbi.nlm.nih.gov/pubmed/? term=Rojansky%20N%5BAuthor%5D&cauthor=true&cauthor_uid=16167908). Beh?et"s disease and pregnancy. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/16167908#comments)Acta Obstet Gynecol Scand. (http://www.ncbi.nlm.nih.gov/pubmed/16167908) 2005 Oct;84(10):939-44.